InnoCan Pharma Corporation (INNO)

Innocan Pharma Announces Closing of Additional DebentureApril 6, 2026 6:54 AM
PR Newswire (US)

HERZLIYA, Israel and CALGARY, AB, April 6, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of an additional debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $200,000 (the "Offering"). This follows the completion of the offering to Tamar Innovest of a debenture in the principal amount of $450,000 on March 11, 2026.
The Debenture will bear interest at the rate of 10% per annum and matures at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed public offering in the United States pursuant to its registration statement on F-1 filed with the U.S. Securities and Exchange Commission, as amended. The Debenture is secured by the general security agreement already entered into by the parties on March 7, 2025 and related security interest filed under the laws of the Province of Alberta.Related Party Transaction DisclosureTamar Innovest currently beneficially owns and controls 765,020 Common Shares representing 17.00 % of the current issued and outstanding Common Shares and is an insider of the Company. Tamar Innovest is managed by Ralph Bossino, a director of the Company. As such, Tamar Innovest's participation in the Offering constitutes a "related party transaction" under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company intends to rely on the exemptions from the valuation and the minority approval requirements of MI 61-101 provided for in subsections 5.5(a) and 5.7(a) of MI 61-101, respectively, as the fair market value of the Offering will not represent more than 25% of the Company's market capitalization as determined in accordance with MI 61-101. The Offering has been approved by the directors of the Company who are independent in connection with such transactions.GeneralThis news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or "U.S. Persons", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.The Company website is www.innocanpharma.com. For further information, please contact:For Innocan Pharma Corporation:
Iris Bincovich, CEO+ 15162104025
+972-54-3012842
+442037699377
info@innocanpharma.comNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Caution regarding forward-looking informationCertain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions relating to the Offering, including the terms, timing, potential completion, and the use of proceeds of the Offering.Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: the ability of the Company to satisfy the conditions of closing of the Offering; that the Offering may not be completed on the terms and timeline indicated, or at all; that the Company's use of proceeds of the Offering may differ from those indicated; global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public disclosure and filings which are available under Innocan's profile at www.sedarplus.ca. Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg 



View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-additional-debenture-302734621.html

Original: Innocan Pharma Announces Closing of Additional Debenture

Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6MMarch 31, 2026 3:04 AM
PR Newswire (US)

HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended December 31, 2025.
Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.Our pharmaceutical segment is dedicated to developing innovative, non-opioid solutions for chronic pain management in both humans and animals, leveraging our proprietary drug delivery technology.In parallel, our wellness segment offers a diverse portfolio of beauty products designed to promote a healthier, more balanced lifestyle.Throughout the year, we continued to demonstrate resilience and solid profitability, while further strengthening the Company's balance sheet.Looking ahead, we are making strong progress toward the next key milestone: a U.S. public offering, aimed at creating value for our investors."FISCAL 2025 SELECT FINANCIAL RESULTS (audited)(US$ in millions)Year Ended
December 31Percentage Change20252024Revenues26.61229.437(9.6 %)Gross Profit23.93126.187(8.6 %)Gross Margin89.9 %89.0 %
Operating Loss(1.255)(1.247)0.7 %Revenues totaled US $26.6 million, representing a decrease of 9.6% on a reported basis for the year ended December 31, 2025.Gross Profit totaled US $23.9 million representing a decrease of 8.6% on a reported basis for the year ended December 31, 2025.Gross Margin remained high at 89.9% despite the decline in revenues in the year ended December 31, 2025.Operating loss remained stable totaled US $1.255 million, representing an increase of 0.7% on a reported basis for year ended December 31, 2025.Sales trends are improving, with declines moderating quarter over quarter and momentum carrying into Q1 2026. Our gross margins remain strong — a testament to the durability of our model and the quality of our execution. B.I. Sky Global continues to lead across all categories and hold its ground on Amazon," said Roni Kamhi, CEO of B.I. Sky Global and COO of Innocan Pharma. "We moved quickly to address tariff headwinds and streamline our supply chain, generating significant cost savings and improved profitability. These steps have made us more resilient and better positioned to deliver strong results — and lasting value for our investors — as the market recovers. Innocan Pharma remains firmly committed to its strategic goals and delivering sustainable growth across the personal wellness, veterinary, and pharmaceutical sectors. In veterinary medicine, this commitment is reflected in concrete results — including CVM recognition of Innocan's innovative LPT technology targeting chronic pain in animals, validated by a placebo-controlled study published in a leading peer-reviewed veterinary journal. On the pharmaceutical side, the Company continues to advance along an FDA-supported regulatory pathway, underscoring the scientific credibility and commercial potential of its pipeline."The Company's full set of audited condensed interim consolidated financial statements for the year ended December 31, 2025, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.innocanpharma.com and its SEDAR+ profile at www.sedarplus.ca.About InnocanInnocan is a pharmaceutical company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients' quality of life. This segment includes its primary drug delivery technology, LPT-CBD loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: pain management and epilepsy. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan is a 60% shareholder in the joint venture company, BI Sky Global Ltd., which company focuses on advanced targeted online sales. https://innocanpharma.com/For further information, please contact:For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
info@innocanpharma.comNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Cautionary note regarding forward-looking informationCertain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.Logo: https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg 



View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-2025-financial-results-with-revenues-at-us-26-6m-302729647.html

Original: Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M

Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar InnovestMarch 16, 2026 5:05 PM
PR Newswire (US)

HERZLIYA, Israel and CALGARY, AB, March 16, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of a debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $450,000 (the "Offering").
The Debenture will bear interest at the rate of 10% per annum and matures at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed public offering in the United States pursuant to its registration statement on F-1 filed with the U.S. Securities and Exchange Commission, as amended. The Debenture is secured by the general security agreement already entered into by the parties on March 7, 2025 and related security interest filed under the laws of the Province of Alberta.Innocan intends to use the proceeds of the Offering for working capital, related cost of the NYSE listing and general corporate purposes. Iris Bincovich, Innocan's CEO stated, "We are delighted to receive an additional investment from our largest shareholder, Tamar Innovest".Related Party Transaction DisclosureTamar Innovest currently beneficially owns and controls 765,020 Common Shares representing 17.00 % of the current issued and outstanding Common Shares and is an insider of the Company. Tamar Innovest is managed by Ralph Bossino, a director of the Company. As such, Tamar Innovest's participation in the Offering constitutes a "related party transaction" under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company intends to rely on the exemptions from the valuation and the minority approval requirements of MI 61-101 provided for in subsections 5.5(a) and 5.7(a) of MI 61-101, respectively, as the fair market value of the Offering will not represent more than 25% of the Company's market capitalization as determined in accordance with MI 61-101. The Offering has been approved by the directors of the Company who are independent in connection with such transactions.About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.The Company website is www.innocanpharma.com.  For further information, please contact:For Innocan Pharma Corporation:Iris Bincovich, CEO
+ 15162104025
+972-54-3012842
+442037699377
info@innocanpharma.comNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Caution regarding forward-looking informationCertain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions relating to the Offering, including the terms, timing, potential completion, and the use of proceeds of the Offering.Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: the ability of the Company to satisfy the conditions of closing of the Offering; that the Offering may not be completed on the terms and timeline indicated, or at all; that the Company's use of proceeds of the Offering may differ from those indicated; global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public disclosure and filings which are available under Innocan's profile at www.sedarplus.ca.Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.Logo: https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg



View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-a-debenture-to-its-largest-shareholder-tamar-innovest-302715192.html

Original: Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest

Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar InnovestMarch 11, 2026 6:42 PM
PR Newswire (Canada)

HERZLIYA, Israel and CALGARY, AB, March 11, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $450,000 (the "Offering").
The Debenture will bear interest at the rate of 10% per annum and will mature at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed public offering in the United States pursuant to its registration statement on F-1 filed with the U.S. Securities and Exchange Commission, as amended. The Debenture will be secured by the general security agreement already entered into by the parties on March 7, 2025 and related security interest filed under the laws of the Province of Alberta.The Offering is expected to close on or around March 12, 2026. Innocan intends to use the proceeds of the Offering for working capital, related cost of the NYSE listing and general corporate purposes.Iris Bincovich, Innocan's CEO stated, "We are delighted to receive an additional investment from our largest shareholder, Tamar Innovest".Tamar Innovest currently beneficially owns and controls 765,020 Common Shares representing 17.00 % of the current issued and outstanding Common Shares and is an insider of the Company. Tamar Innovest is managed by Ralph Bossino, a director of the Company. As such, Tamar Innovest's participation in the Offering constitutes a "related party transaction" under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company intends to rely on the exemptions from the valuation and the minority approval requirements of MI 61-101 provided for in subsections 5.5(a) and 5.7(a) of MI 61-101, respectively, as the fair market value of the Offering will not represent more than 25% of the Company's market capitalization as determined in accordance with MI 61-101. The Offering has been approved by the directors of the Company who are independent in connection with such transactions.This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or "U.S. Persons", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.The Company website is www.innocanpharma.com.  For further information, please contact:For Innocan Pharma Corporation:
Iris Bincovich, CEO
+ 15162104025
+972-54-3012842
+442037699377
info@innocanpharma.comNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Caution regarding forward-looking informationCertain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions relating to the Offering, including the terms, timing, potential completion, and the use of proceeds of the Offering. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: the ability of the Company to satisfy the conditions of closing of the Offering; that the Offering may not be completed on the terms and timeline indicated, or at all; that the Company's use of proceeds of the Offering may differ from those indicated; global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public disclosure and filings which are available under Innocan's profile at www.sedarplus.ca.Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/innocan-pharma-announces-offering-of-a-debenture-to-its-largest-shareholder-tamar-innovest-302711582.htmlSOURCE Innocan Pharma Corporation

Original: Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest

Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in DogsFebruary 9, 2026 9:07 AM
PR Newswire (Canada)

HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial" in the esteemed peer reviewed journal Frontiers in veterinary science (https://doi.org/10.3389/fvets.2025.1746266) (1).
Key findings include:Significant improvement in behavior/function reported by owners (p = 0.0217), with 100% of dogs showing improved function after LPT-CBD vs 25% after placebo.Significant reduction in lameness (Visual Lameness Scale; p = 0.033) and pain (interactive VAS; p = 0.005) following LPT-CBD administration in comparison to placebo.LPT-CBD injection provided a sustained-release profile, with measurable plasma CBD concentrations lasting up to 4 weeks.All dogs tolerated LPT-CBD, with only minor, self-resolving adverse events: a short-lived (~2-day) fever and a transient injection-site swelling that was resolved within a few days without treatment.In follow-up to our recent publication demonstrating the long-acting effects of LPT-CBD in dogs with osteoarthritis (2), the present study evaluated LPT-CBD effect compared with placebo. Eight clients-owned dogs suffering from naturally occurring osteoarthritis received two subcutaneous injections in a randomized, blinded, crossover design: synthetic CBD in liposomes (LPT-CBD) 7 mg/kg and placebo (empty liposomes of identical amount and lipid composition) administered four weeks apart. Throughout the study, serial blood sampling was performed to assess CBD and its metabolite plasma concentrations and to evaluate hematological and biochemical profiles before and up to 4-weeks post-injections. Efficacy was assessed via activity monitoring collar and scorings by owners and two veterinary specialists.This study demonstrates that a single subcutaneous injection of LPT-CBD produced sustained improvements in long-term pain-related outcomes and overall, wellbeing in client-owned dogs with naturally occurring osteoarthritis for up to four weeks, with a statistically significant superiority over placebo. The observed clinical benefit is concordant with sustained plasma CBD concentrations persisting for up to four weeks following administration."LPT-CBD has been repeatedly demonstrated to have a pain relief effect across multiple efficacy studies in dogs, goats, and other animals," said Professor Chezy Barenholz, Head of the Advisory Board. "However, this study is particularly important because it shows the clear advantages of LPT-CBD over the liposomal placebo."Dr. Eyal Kalo, Vice President of Research and Development, added: "We are encouraged by these results, particularly given LPT-CBD's potential as a long-acting approach to pain management in both veterinary and human settings. We have initiated ongoing discussions with FDA, including the Center for Veterinary Medicine (CVM) and the human analgesic and anesthetic department of the FDA, to support the advancement of LPT-CBD across both markets."Reference:
(1) Yael Shilo-Benjamini et al, Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial, Front. Vet. Sci., 19 January 2026.
(2) Yael Shilo-Benjamini et al, Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis, Front. Vet. Sci., 23 August 2023.About Innocan:Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.www.innocanpharma.comContact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.comNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Caution Regarding Forward-Looking InformationCertain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.Logo: https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg



View original content:https://www.prnewswire.com/news-releases/innocan-pharma-announces-lpt-cbd-demonstrates-pain-relief-over-placebo-results-from-a-randomized-blinded-clinical-study-in-dogs-302682620.htmlSOURCE Innocan Pharma Corporation

Original: Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs

https://otce.finra.org/otce/dailyList

09/04/2025 00:00:00 Reverse Split/CUSIP Change 09/05/2025 00:00:00 INNPF Innocan Pharma Corp Common Stock (Canada) OTC Equity

Big catalyst for INNO, files patent application for its CBD-loaded exosome and liposome platform tech:
https://finance.yahoo.com/news/innocan-pharma-announces-filing-pct-201200126.html

No better time to buy the dip ! IMHO

Hit ATH at $1.65 last week!

InnoCan Pharma receives strong buy recommendation:
https://finance.yahoo.com/innocan-pharma-receives-strong-buy-092917133.html

What happened to the board???

?????

Where is the board for this ticker?

FDA approval.

Up to 0,35 Today CAD/$ ...

https://www.finanznachrichten.de/nachrichten-2020-05/49598639-internationale-medien-berichten-ueber-cbd-als-moeglichen-covid-19-killer-aktie-legt-weiter-zu-314.htm

InnoCan Pharma Collaborates with Tel Aviv University.

InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD


https://www.newsfilecorp.com/release/54575/InnoCan-Pharma-Collaborates-with-Tel-Aviv-University-to-Develop-a-New-Revolutionary-Approach-to-Treat-the-COVID19-Corona-Virus-with-ExosomesLoaded-CBD